Contract Win

Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company's mass spectrometry services for the analysis of samples for an on-going clinical trial. This project will be provided utilising the Good Clinical Laboratory Practice ("GCLP") accreditation obtained by Proteome Sciences specifically for this type of project. The contract value is in excess of US$1m and the Company considers that a significant proportion of the work should be completed in the current financial year and into 2026.

Commenting on the contract, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:

"In April 2024 we announced the first contract from this customer and commented that we expected additional contracts to be received from them in the near future. This contract represents a further targeted assay that we will perform under GCLP compliance to monitor drug performance in an ongoing clinical trial. As in 2024 we are seeing increasing interest for GCLP work from other major biopharma clients in both the US and Europe and expect additional orders to follow in 2025."